Phase 2 Study of SAR445877 for ICI-refractory Non-Small Cell Lung Cancer
This study is testing a drug called SAR445877 in people with non-small cell lung cancer (NSCLC) that has not responded to previous immunotherapy (ICI-refractory). The main goal is to see how safe SAR445877 is and what side effects it might cause. Researchers also want to find out if SAR445877 can help control the cancer. You might be able to join if you are 18 years or older, have NSCLC that didn't respond to immunotherapy, and are willing to sign an informed consent form. This study aims to enroll 29 participants.
- Study design
- This is a Phase 2 interventional study, meaning it tests a new treatment in a small group of people. It plans to enroll 29 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and side effects will be monitored through study completion, which is expected to be an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Natalie Vokes, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0